Clinical trials: Transarterial Chemoembolization
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Hepatocellular Carcinoma (HCC)
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic…
- Trial name
- TACE HCC (NCT06990620)
- Testing
- TACE+AK112
- Volunteers
- 56 people
- Sponsor
- Fudan University
Nodular Goiter
TACE Treats Nodular Goiter
transarterial bleomycin chemoembolization represents a novel minimally invasive therapeutic approach for the management of giant nodular goiter.
- Trial name
- NCT07258199
- Testing
- TACE
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Hepatocellular Carcinoma
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
- Trial name
- TACE (NCT03905967)
- Testing
- TACE, Lenvatinib
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Hepatocellular Carcinoma, Transarterial Chemoembolization
Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization
- Trial name
- NCT07178093
- Testing
- Antrodia cinnamomea
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taichung Tzu Chi Hospital
PHENYTOIN/SORAFENIB [VA Drug Interaction], Carcinoma, Hepatocellular
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
TACE is widely used in patients with unresectable HCC. However, it is a non-curative approach; thus ,strategies to further improve the survival of these patients are needed.
- Trial name
- NCT01605734
- Testing
- TACE, sorafenib combined with TACE
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Shandong Cancer Hospital and Institute
Potentially Resection, Hepatocellular Carcinoma
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- NCT03591705
- Testing
- TACE-HAIC, HAIC
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Adjuvant Therapies for Patients With HCC and MVI
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades.
- Trial name
- A-TACE/S-HCC (NCT02436902)
- Testing
- TACE, Sorafenib, TACE plus sorafenib
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
- Trial name
- EMERALD-1 (NCT03778957)
- Testing
- Durvalumab, Bevacizumab, Transarterial Chemoembolization (TACE)
- Where
- 166 sites in United States, Australia and 16 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Carcinoma, Hepatocellular
Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma
Developed in Japan in the 1980s, TACE became the most frequent treatment for unresectable hepatocellular carcinoma (HCC) in patients with preserved hepatic function after 2002, when two radiochemotherapies (RCTs) showed survival…
- Trial name
- RAD-18-TAcE (NCT04803019)
- Testing
- DEB-TACE, TAE
- Where
- Italy
- Volunteers
- 154 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Thrombocytopenia, Hepatocellular Carcinoma
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
This study is conducted to evaluate the efficacy of avatrombopag for thrombocytopenia in patients with hepatocellular carcinoma (HCC) who intend to undergo transarterial chemoembolization (TACE) and/or hepatic arterial infusion…
- Trial name
- NCT06001567
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
HCC
Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy
This study is a prospective phase II, single arm clinical study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and…
- Trial name
- START-FIT (NCT03817736)
- Testing
- TACE, SBRT, Immune Checkpoint Inhibitor
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
Antibiotic Prophylaxis
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess. There would be two comparison groups.
- Trial name
- NCT05654896
- Testing
- Ceftriaxone Sodium
- Where
- Pakistan
- Volunteers
- 158 people
- Sponsor
- Nadeem Iqbal
Cholangiocarcinoma
International Registry on Cholangiocarcinoma Treatment
Cholangiocarcinoma is a rare and very aggressive neoplasm that arises from the biliary epithelium, constitutes approximately 2% of all reported cancer, and accounts for about 3% of all gastrointestinal malignancies.
- Trial name
- CHOLANGIO (NCT01920503)
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
Combination Treatment for Advanced Liver Cancer
The purpose of this study is to determine whether TACE combined endovascular stent implantation confers a survival benefit over TACE alone.
- Trial name
- NCT02149771
- Testing
- chemoembolization, endovascular stents implantation, iodine-125 seed strand implantation
- Where
- China
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs.
- Trial name
- NCT01327521
- Testing
- CyberKnife, TACE, CT Contrast
- Where
- United States
- Sponsor
- Albert Koong
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC.
- Trial name
- NCT04803994
- Testing
- Atezolizumab, Bevacizumab, TACE
- Where
- 72 sites in Austria, France and 4 more
- Volunteers
- 434 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest